Kornimate/medical-research-clean huggingface dataset:
the effects of a high-fiber formula in children with failure to thrive

Conditions: GI Tolerance

Summary: the present study is designed to determine the gastrointestinal tolerability of enteral nutritional products, physicians and parents' overall perception of enteral nutrition products as well as providing basic demographic information on pediatric populations prescribed these formula for supportive treatment as part of the routine healthcare service in turkey.


Eligibility criteria:
inclusion criteria: * age; 1-10 years (inclusive) * children diagnosed as failure-to-thrive(ftt). * children who have been recently prescribed and treatment initiated with isocaloric or hypercaloric high-fiber pediatric enteral formula suitable for oral and/or nasogastric tube feeding before inclusion in the study. exclusion criteria: * chronic renal disorder * decompensated liver disease * any other chronic condition that was not under control (e.g. diabetes, thyroid disorder, etc.) * any type of malignant disease including leukemia and lymphoma * cystic fibrosis * short bowel syndrome * any type of food allergy or intolerance * growth hormone deficiency * use of enteral feeding within the last 4 weeks
effects of fasting and hydro colon therapy plus probiotics on gi microbiota in intolerances and irritable bowel syndrome

Conditions: Irritable Bowel Disease

Summary: consequences of colon hydrotherapy plus probiotic intervention on composition of gi microbiota and well being are analysed in subjects claiming gi inconveniences due to irritable bowel syndrome or food intolerances.

study objectives: analysis of consequences of hydro colon therapy plus probiotic intervention on gi microbiota and well being. study group: 78 subjects, inclusion criteria: 20-50yrs; under consultation at doctors or nutritionists because of claimed food inconveniences or irritable bowel syndrome. exclusion criteria: antibiotics treatment and specified complex diseases. intervention: hydro colon therapy 2- 5 washes within 3 weeks. probiotic intervention after end of hydro colon therapy for 6 weeks ( duolac® bacterial strains per capsule: lactobacillus plantarum, streptococcus thermophiles, lactobacillus acidophilus, lactobacillus rhamnosus, bifidobacterium lactis, bifidobacterium longum, and bifidobacterium breve, fructooligosaccharides, 200 µg folic acid, 2.50 µg vitamin b12 and 55 µg selenium (all amounts corresponding to 100% of daily requirement). control group: vitamin b complex: 10µg cobalamin, 450µg folic acid, and 55 µg selenium. sample collection: standardized feces collection, t1, before colon hydrotherapy, t2, immediately after colon hydrotherapy 2-5 washes of fasting ; t3, after six weeks of probiotic or control intervention analysis: standardizes food frequency questionnaire before and after intervention. feces analysis based on 16 s ribosomal dna (rdna) pcr dgge and quantitative pcr (qpcr) and bioinformatic analysis.

Eligibility criteria:
inclusion criteria: * subjects under consultation at doctors or nutritionists for inflammatory bowel syndrome (ibd) of food intolerances exclusion criteria: * pregnancy * antibiotic therapy 0,5 yrs before start * hormone therapies * malignant diseases * subjects were asked to avoid dietary supplements 4 weeks before and during the study.

Keywords: irritable bowel disease microbiota hydro colon therapy food intolerance
exercise echocardiography on lv mechanics in patients with cad: a speckle-tracking echocardiography

Conditions: Cardiovascular Diseases; STEMI; NSTEMI

Summary: recovering blood flow to a coronary stenosis may improve left ventricular (lv) function in patients with coronary artery disease (cad). however, the reported data about evaluation of lv function post-percutaneous coronary intervention (pci) in cad was limited. the aim of this study was to compare the lv function measured by 3 min low dose exercise stress echocardiography (ese) combined 2d speckle tracking echocardiography (ste) in patients with cad underwent pci, and to identify factors affecting the change of lv function. patients with cad who underwent acute pci were enrolled.

the assessment of temporal changes in systolic and diastolic regional left ventricle function by 2d-ste after successful reperfusion therapy of acute myocardial infarction (ami).the estimated total number of participants is 90 patients with ami and treated with successful percutaneous coronary intervention were included in this study. the echocardiographic measurements were performed in all patients within in-hotpital after pci procedure, and then followed up at 7, 14, 30, 60 and 180 days after discharge. recovery of regional systolic and diastolic myocardial function after acute myocardial infarction evaluated by ese-ste.

Eligibility criteria:
inclusion criteria: * acute myocardial infarction diagnosed by a physician * undergoing percutaneous coronary intervention * exercise testing and stress echocardiography are performed with the approval of the physician. exclusion criteria: * severe cardiac valve disease * left bundle branch block * uncontrolled diabetes or hypertension * orthopedics or other conditions that hinder from exercise * uncontrolled sinus tachycardia (greater than 120 beats per minute)

Keywords: stress echocardiography speckle tracking
gut microbiota changes of hiv patients before and after one year of art

Conditions: HIV Infections

Summary: hiv infection leads to destruction of cd4+t cells in the gut-associated lymphoid tissue (galt) and promotes a decline in mechanical barrier functions of the gut mucosa, and the subsequent translocation of microbial products from the gastrointestinal tract to systemic circulation. the gut mucosal immune system is not completely restored by cart, and the resultant microbial translocation may contribute to chronic inflammation, inadequate cd4 t-cell recovery, and increased rates of serious non-aids events. many studies have revealed strong and characteristic compositional differences in gut microbiota between individuals with hiv infection and seronegative controls. so far, several probiotic organisms have shown the ability to enhance intestinal epithelial barrier functions, reduce inflammation, and support effective th-1 responses. probiotics mainly stimulates polymeric iga secretion, avoid bacterial overgrowth and their translocation, and produce a self-limited inflammatory response through development of regulatory t (treg) cells by anti-inflammatory cytokine production. therefore, we design a prospective, randomized, double-blind, placebo-controlled study to determine whether the use of a probiotic can expand beneficial microbiota that aid in decreasing bacterial translocation and pro-inflammatory cytokine production, thereby improving immune functions in hiv-infected subjects. participants in the intervention group will receive oral probiotic containing 3 billion bifidobacterium and 1 billion lactobacillus once daily, while those in the placebo group will take placebo which contains no probiotic but has the same flavor and characteristics as the probiotic product.. gut bacterial community diversity and composition, immune recovery and activation in peripheral plasma, plasma levels of gut damage, microbial translocation and inflammation at baseline and after 12 months of receiving intervention will be analyzed.


Eligibility criteria:
inclusion criteria: * 18-65 years old; * documented hiv infection; * no history of gastrointestinal diseases; * good adherence and promise to follow-up; * ability to provide informed consent. exclusion criteria: * administration of antibiotics, probiotics, or prebiotics or experience of diarrhea within the previous 3 months; * administration of anti-inflammatory drugs, corticosteroids, immunosuppressive drugs, immunomodulator within the previous 3 months; * severe organ dysfunction; * pregnancy or breastfeeding.
the effect of hydrodissection for carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: carpal tunnel syndrome (cts) is the most common peripheral entrapment neuropathy with involving compression of the median nerve in the carpal tunnel. rather than other progressive disease, cts is characterized by remission and recurrence. the hydrodissection could decrease the entrapment of nerve to restore blood supply. despite the hydrodissection was pervasively used in clinical practice, current researches contain small participant without control group or randomized leading to foreseeable selection bias. the investigators design a randomized, double-blind, controlled trail to assess the effect after ultrasound-guided hydrodissection in patients with cts.

after obtaining written informed consent, patients with bilateral cts will been randomized into intervention and control group. participants in intervention group received one-dose ultrasound-guided hydrodissection and control side received one-dose ultrasound-guided injection at subcutaneous layer beyond carpal tunnel. no additional treatment after injection through the study period. the primary outcome is visual analog scale (vas) and secondary outcomes include boston carpal tunnel syndrome questionnaire (bctq), cross-sectional area (csa) of the median nerve, sensory nerve conduction velocity of the median nerve, and finger pinch strength. the evaluation was performed pretreatment as well as on the 2nd week, 1st, 2nd and 3rd month after the treatment.

Eligibility criteria:
inclusion criteria: * age between 20-80 year-old. * diagnosis was confirmed using an electrophysiological study exclusion criteria: * cancer * coagulopathy * pregnancy * inflammation status * cervical radiculopathy * polyneuropathy, brachial plexopathy * thoracic outlet syndrome * previously undergone wrist surgery or steroid injection for cts

Keywords: hydrodissection
the effect of branched-chain amino acid on the improvement of serum albumin level in cirrhotic patients with ascites

Conditions: Cirrhosis; Ascites

Summary: to compare the efficacy of branched-chain amino acid in serum albumin level in cirrhotic patients with ascites.

branched-chain amino acid (bcaa) is known to reduce the relapse rate of liver cancer as it is associated with insulin resistance and has been reported to improve the progression of liver fibrosis when used in combination with an angiotensin-converting enzyme. with regard to the effect of liver function improvement, in a research conducted in south korea, approximately 41.2% of the patients showed recovery of the normal albumin level when bcaa was administered to them for about 10 weeks during radiation therapy for liver cancer. additionally, in other overseas researches, the changes in the values of total protein and albumin were significantly smaller in the patients who underwent transarterial chemoembolization (tace) to whom bcaa was administered than in those to whom bcaa was not administered. the hypothesis of this study is that the serum albumin value will be increased significantly in the cirrhotic patients with ascites to whom bcaa is administered than the patients to whom placebo is administered.

Eligibility criteria:
inclusion criteria: * age ≥ 19 and ≤ 70 years; * presence of liver cirrhosis * serum albumin level ≤ 3.5g/dl, ultrasound or ct scan confirmed ascites (≥grade 1) * no administration of diuretics and bcaa within the past 1 week * voluntary consent to take part in this trial exclusion criteria: * child-pugh score \> 12 * having been diagnosed as hcc within the past 5 years * serum creatinine \> 1.5mg/dl * serum bilirubin \> 5.0mg/dl * presence of such complications as sbp, or hepatic encephalopathy(west haven grade ≥ 3) * patients who experienced organ failure by acute exacerbation of liver cirrhosis within the past 1 month * presence of serious cardiac or respiratory disease * contraindicated to either diuretics or bcaa * having commenced anti-viral treatment against hepatitis c, b within the past 1 month * pregnant or lactating women * chronic alcohol taker * woman patients who do not agree to the contraception from baseline to 12 month * unsuitable patients judged by investigator * patients participating in another clinical trial within 1 month
randomized trial comparing endoscopy and surgery for pancreatic cyst-gastrostomy

Conditions: Pancreatic Pseudocysts

Summary: patients with pancreatitis can develop inflammatory fluid collection around the pancreas called pseudocysts. pseudocysts may cause abdominal pain when they are more than 6cm in size. these pseudocysts can be treated (drained) by surgery or by endoscopy. both treatment options are the current standard-of-care at all institutions around the world. the aim of this study is to identify the better of the two techniques, surgery versus endoscopy, for treatment of patients with pancreatic pseudocysts. this will be done by comparing a) the rates of pseudocyst recurrence b) quality of life of patients following treatment and c) cost associated with treatment, between both treatment modalities.

the purpose of this study is to examine endoscopic ultrasound guided celiac plexus neurolysis (cpn) with analgesic therapy in patients with unresectable pancreatic cancer will decrease the severity of abdominal pain when compared to analgesic therapy alone. the specific primary aim of this study is to evaluate the efficacy of eus-cpn + analgesic therapy (group 1) in pain relief of patients with unresectable pancreatic cancer when compared with analgesic therapy (group 2). the hypothesis will be tested by comparing the changes in reported pain severity between those who receive eus-cpn in addition to analgesic therapy as compared to analgesic therapy alone.

Eligibility criteria:
inclusion criteria: * age \> 19yrs * able to provide informed consent * pancreatic pseudocyst by ct exclusion criteria: * age \< 19yrs * unable to consent * pancreatic abscess or necrosis
vildagliptin versus liraglutide - patient preference after receiving both medications

Conditions: Type 2 Diabetes

Summary: dipeptidyl peptidase-4 (dpp-4) inhibitors and glucagonlike peptide-1 (glp-1) mimetics or analogs, which rely on the gastrointestinal hormones that are part of the incretin system for the treatment of t2dm, provide a therapeutic alternative to common oral antihyperglycemic agents (eg, sulfonylureas, thiazolidinediones). although glp-1 analogs and dpp-4 inhibitor medications are effective, there are differences between these products, including method of administration (injectable versus oral). previous studies have shown that patients prefer additional oral agents over injectable agents because of fear of injections and the desire to avoid them. patient preference is both clinically and financially important, as it can have long-term implications in terms of patients' motivation and insight into their disease state and its treatment, which might have a direct impact on the patient's compliance and treatment adherence. the aim of the current study is to evaluate the proportion of t2dm patients preferring oral anti-diabetic treatment with vildagliptin + metformin versus an injectable anti-diabetic treatment with liraglutide after 4 weeks of treatment with each medication.


Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes * metformin monotherapy \> 12 weeks * hemoglobin a1c (hba1c) \> 6.5 % and \< 9.0 % * body mass index (bmi) 19-35 (kg/m²) exclusion criteria: * acute diseases at randomization * kidney diseases with creatinin \> 120 µmol/l, glomerular filtration rate (gfr) \<50 ml/min * contraindication for gliptins or glucagon-like-peptide-analogues according to the respective summary of product characteristics (smpc) * previous use of dipeptidyl peptidase-4-inhibitors and glp-1-mimetics other protocol-defined inclusion/exclusion criteria may apply.

Keywords: patient preference vildagliptin liraglutide
study of aripiprazole in the treatment of patients with acute symptoms in bipolar disorder

Conditions: Bipolar Disorder

Summary: the purpose of this study is to learn if aripiprazole is effective for the treatment of patients with acute symptoms of bipolar disorder.


Eligibility criteria:
inclusion criteria: patients with acute symptoms of bipolar disorder

Keywords: bipolar i disorder
prognostic impact of increased lymph node yield in colorectal cancer patients with synchronous distant metastasis: a population-based study of the us database and a chinese registry

Conditions: Colorectal Cancer Stage IV; Lymph Node Yield

Summary: the national quality forum has endorsed at least 12 lymph node yield (lny) as a surgical quality indicator in colorectal cancer (crc), but the prognostic value of adequate lymphadenectomy has rarely been investigated for crc patients with distant metastatic disease.

data on crc patients with synchronous liver metastasis (lm) were derived from the us surveillance, epidemiology, and end results (seer) and a chinese registry (from two chinese tertiary centers: the second affiliated hospital of harbin medical university and national cancer center/cancer hospital, chinese academy of medical sciences \& peking union medical college) between january 2010 and december 2017. individual level data on patients with incident crc were consecutively collected in both registries. the primary tumor site was divided into three subsites according to international classification of diseases for oncology (icd-o-3) topography codes: proximal colon (c18.0, c18.1, c18.2, c18.3 and c18.4), distal colon (c18.5, c18.6, c18.7) and rectum (c19.9 and c20.9). the synchronous lm were identified by imaging or histopathological examinations. synchronous lm refers to liver lesions found within 6 months after the diagnosis of primary crc. patients were excluded if they did not undergo surgery for crc, did not have data on number of lns retrieved and their survival status was unknown.

Eligibility criteria:
inclusion criteria: * data on crc patients with synchronous liver metastasis (lm) undergo surgery for crc, have data on number of lns retrieved and their survival status was known exclusion criteria: * patients were excluded if they did not undergo surgery for crc, did not have data on number of lns retrieved and their survival status was unknown
to evaluate the therapeutic effect of laser acupuncture in patients with acute or subacute post stroke shoulder pain

Conditions: Post Stroke Shoulder Pain

Summary: investigators propose a research design protocol to evaluate the efficacy of laser acupuncture in improving shoulder pain and improving shoulder function recovery after stroke.

shoulder pain after stroke, also known as hemiplegic shoulder pain, is one of the common complications after stroke. the overall incidence rate increases with the time after stroke.the existing treatment methods for shoulder pain after stroke are divided into non-drug and drug. investigators propose a research design protocol to evaluate the efficacy of laser acupuncture in improving shoulder pain and improving shoulder function recovery after stroke.

Eligibility criteria:
inclusion criteria: * beyond the age of 20. * normal consciousness before and after stroke who can reply and fill in the questionnaire. * subacute (subacute phase: 7 days to 6 months after stroke) and chronic (chronic phase: more than 6 months after stroke) with shoulder pain after stroke and in post- stroke recovery period. * stop taking painkillers for more than 1 day, * without received intramuscular drugs (steroids, botulinum toxin, glucose, etc.) injections in the shoulder joint or around the shoulder for more than 2 weeks * those willing to sign the written subject consent form. exclusion criteria: * participants with shoulder pain symptoms before the stroke * acute shoulder trauma on the affected side of shoulder pain in the past. * surgery on the affected side of shoulder pain in the past. * those who cannot complete the scale assessment due to aphasia, post-stroke depression, and obvious cognitive impairment. * women who are pregnant or planning to become pregnant. * those who have a history of epilepsy and are receiving anti-epileptic drug treatment. * who are receiving any herbal or folk remedies related to shoulder pain. * any other conditions deemed unsuitable in the assessment of the responsible physician. * those who have not signed the written subject consent form.
comparison of conservative treatment options in the management of erectile dysfunction

Conditions: Erectile Dysfunction

Summary: this is a randomized clinical trial study with the formation of three groups. after signing the informed consent form, in two copies of equal content, the patient will be evaluated by an experienced physiotherapist and will answer a questionnaire of socio-demographic data and basic anamnesis. then, in a private and individualized room, participants will be guided by researchers trained to complete the self-administered questionnaires: international erectile function index (iife), erection quality questionnaire (eqq), sf-36 and hospital anxiety scale and depression (ehad). after applying the questionnaires, a physical evaluation by an experienced physiotherapist will be performed. to induce erection of the penis an injection of a vasoactive agent (prostaglandin e1, alprostadil) will be administered in the corpora cavernosa. then the length of the penis (swollen, elongated and flaccid) and penile circumference will be measured. soon after, dynamic doppler ultrasonography with penis doppler (uddp) will be performed. the parameters that will be used in the uddp to provide a general vascular diagnosis include peak systolic speed (vsp), final diastolic speed (vdf) and resistive index (ir). in the case of a controlled and randomized clinical trial, the patient may be randomly allocated to one of three groups: the non-ablative radiofrequency group (narft); the low intensity shockwave therapy group (liswt) and; the sham group that will perform the vacuum therapy (sham). in the narft group, the radio frequency will be applied, the device used will be the hertix radiofrequency. the shock wave therapy application protocol in the liswt group will use the thork shock wave. while in the sham group, the vacuum therapy will be used, the research subjects will use the automatic version with simple on / off and release valve commands. as in the other groups, participants in the sham group will have a session every seven days for eight weeks. the entire evaluation protocol will be applied before (pre-test) and after treatment (post-test).


Eligibility criteria:
inclusion criteria: * 30-80 years. * men with a report of complaints of erectile dysfunction. exclusion criteria: * history of neurological disease. * history of diabetes mellitus. * history of peyronie's disease. * history of psychiatric illness. * history of prostatectomy. * patients with anatomical malformations in the genital region. * penile prosthesis users.

Keywords: extracorporeal shockwave therapy radiofrequency therapy